
Indonesia is building the legal scaffolding to turn kratom into a pharmaceutical. At the eleventh meeting of the Health Sector Policy Committee (Komite Kebijakan Sektor Kesehatan, or KKSK) in Bogor on Oct. 6, 2026, the government agreed to develop a national policy on kratom as a raw material and extract for health purposes, with research and clinical trials to establish safety and effectiveness. Two indications were named for study: analgesic effects, and reducing opioid dependence. The Indonesia kratom medicine track now has ministries, state-owned drugmakers and universities attached to it, and it arrives in the same six weeks that the United States, Indonesia’s largest customer, draws a hard line around concentrated kratom alkaloids.
🇮🇩 The Indonesia Kratom Medicine Policy, As Actually Agreed
The KKSK is the interministerial body that sets health-sector policy direction. Its Oct. 6 session drew the Ministry of Health, the drug and food authority BPOM, the national insurer BPJS Kesehatan, the financial regulator OJK and the population ministry, with kratom on an agenda that also covered advanced cell therapies and insurance reform.
The committee agreed that a national policy should be drafted covering kratom as a raw material and extract, shaped by benefit, risk, safety, quality and scientific evidence. The agreement is a direction of travel, not a finished regulation: no regulation number was issued, no timeline published, no product approved. BPOM head Taruna Ikrar described the follow-up as a benefit-and-risk review paired with clinical study of several indications, run by BPOM’s deputy for traditional medicine, health supplements and cosmetics with the health ministry.
The same meeting agreed to route oversight of certain medicines through SatuSehat Logistik, the national tracking platform, to which BPOM has connected eleven application interfaces. That matters here: a country hoping to sell a standardized extract needs a chain of custody foreign regulators will recognize.
🔬 From leaf to 98% mitragynine

The industrial half moved a week later. On Oct. 13 the Ministry of Higher Education, Science and Technology convened universities and manufacturers to push kratom research toward commercial scale, with Minister Brian Yuliarto saying the aim is an industry large enough that the country’s resources are not wasted. Institut Teknologi Sumatera, whose rector Elfahmi attended, is working on extraction and purification, and the target named at that meeting is mitragynine concentration above 98 percent. BRIN, the national research agency, handles the pharmacology. PT Indofarma president director Sahat Sihombing argued for pilot production and market studies before any scale-up.
On Oct. 17, state drugmaker Kimia Farma said it is exploring downstreaming of eight health innovations with BRIN, kratom among them. Commercial director Hanadi Setiarto cautioned that research should not run ahead of what industry can use. No timeline or investment figure was disclosed.
That is a recognizable sequence: a policy mandate, a purification target, a pharmacology partner, two state manufacturers. It is also early. Nothing public shows a registered trial, a BPOM dossier or an approved indication.
📦 Export-only, and still export-only
None of this changes what Indonesians can buy at home. Trade Minister Budi Santoso has stated plainly that kratom cannot yet be sold domestically because the ministry has issued no domestic trade rules for it. Export is tightly specified instead: Trade Ministry regulations No. 20 of 2024 and No. 21 of 2025 set the procedures, and only crumb and powder under 600 microns may ship, since anything coarser counts as unprocessed raw material. The first official export, on Feb. 28, 2025, was 351 tons in 13 containers worth about $1.05 million.
Volume is rationed too. The ministry sets an export rights percentage each half-year: Ministerial Decision No. 32 of 2026 covered January through June, and No. 1522 of 2026, signed June 30, covers July through December. We covered that system in Indonesia’s half-year export quota and the contamination and testing rules in the 2026 export rulebook.
So the Indonesia kratom medicine policy sits on an odd foundation: a crop legal to grow and legal to export, not legal to sell at home, and now a candidate to become an approved drug. A licensed medicine would reach patients through pharmacies under BPOM registration, a different channel entirely from the retail market that stays closed.
⚖️ Washington draws its line in November
The timing is the story. On Oct. 9, 2026 the Department of Health and Human Services recommended that DEA place 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI) in Schedule I only above a threshold: more than 1 milligram per gram in solids or 1 milligram per milliliter in liquids, or a mitragynine-to-alkaloid mass ratio below 100 to 1. Secretary Robert F. Kennedy Jr. described the aim as “drawing a clear line between natural kratom and dangerous, enhanced opioid products.” DEA published the matching notices in the Federal Register on Oct. 14 as documents 2026-20943 and 2026-20942.
A threshold written around 7-OH is not a threshold written around mitragynine. Indonesia’s 98 percent purification target aims at the alkaloid Washington is trying to protect, not the one it is trying to schedule.
Pain News Network reports Nov. 13, 2026 as the earliest effective date, roughly 30 days after publication, though the notices carry no effective date field and DEA has not confirmed one. The American Kratom Association, which sued DEA in July over the original orders, now backs the revised thresholds; lobbyist Mac Haddow said it agreed to dismiss the suit conditioned on publication. The 7-HOPE Alliance disagrees, stressing that a notice of intent is not a scheduling order. We tracked the mechanics in the 1 mg/g and 100:1 ratio test and the clock in why the notice is not the ban.
🌿 Why the two tracks may fit better than they look
Here is the part that gets misread. The US thresholds measure 7-OH and MGPI against mitragynine, while the Indonesia kratom medicine program is purifying mitragynine itself. A highly purified mitragynine extract has, by construction, an enormous mitragynine-to-7-OH ratio, so it passes the ratio test rather than failing it, provided 7-OH stays under the concentration ceiling and nothing is semi-synthetically converted afterward. The federal framework targets products enhanced to behave like opioids; FDA’s review found 7-OH roughly two to nine times more potent than morphine in preclinical studies.
What would not travel easily is the retail route. An isolate is not natural leaf, and states regulate extracts independently of the federal threshold: Kentucky caps 7-OH at 2 percent of the alkaloid fraction and bars synthetically derived compounds, and North Dakota’s HB 1628 caps it at 0.05 percent by dry weight with lab-verified labeling and an annual attorney general license. A pharmaceutical-grade isolate would also need actual drug approval in the US rather than supplement status, a multi-year path. So the realistic near-term US market for Indonesian material stays what it already is: clean, tested, properly milled leaf powder, the one category every live rulebook accommodates. Buyers comparing sellers can check our Kratom Vendors directory.
⚠️ The caveats that belong in the same breath
Studying kratom for opioid dependence is not the same as establishing that it treats it. Indonesia has agreed to run the research, not reported a result. Kratom itself carries a real risk of physical dependence and withdrawal with regular use, and FDA identified evidence of opioid-like dependence and withdrawal specifically for MGPI. Anyone reading a headline about a leaf becoming medicine should read the word “candidate” into it.
The constructive reading is narrow but real. A producer country setting purification standards, wiring up a tracking system and routing claims through clinical trials is building the evidence base this argument has lacked on both sides. That is slower than a press release, and more useful than one.
❓ Frequently asked questions
Did Indonesia legalize kratom as a medicine in October 2026?
No. On Oct. 6, 2026 the Health Sector Policy Committee agreed to develop a national policy on kratom as a drug raw material and extract, supported by research and clinical trials. The Indonesia kratom medicine policy is a direction of travel, not an approval: no regulation number, timeline or approved product has been published.
Can people in Indonesia buy kratom domestically now?
No. The Trade Ministry has said there are still no domestic trade rules for kratom, so it cannot legally be sold inside Indonesia. Kratom remains an export commodity governed by Trade Ministry regulations No. 20 of 2024 and No. 21 of 2025, with export limited to crumb and powder under 600 microns.
What indications is Indonesia planning to study?
Officials named two: analgesic effects, and reducing opioid dependence. These are proposed subjects for clinical study. No efficacy has been established for either use, and kratom itself can cause physical dependence and withdrawal.
Does the DEA threshold ban Indonesian kratom powder?
No. The proposed thresholds target 7-OH and mitragynine pseudoindoxyl above 1 mg/g in solids or 1 mg/mL in liquids, or where the mitragynine-to-alkaloid ratio falls below 100 to 1. Natural leaf powder normally sits far inside those limits. HHS stated the intent was to avoid sweeping natural botanical kratom into Schedule I.
When do the US thresholds take effect?
DEA published its notices of intent in the Federal Register on Oct. 14, 2026 (documents 2026-20943 and 2026-20942). Reporting points to Nov. 13, 2026 as the earliest date an order could take effect, but the notices carry no effective date field and DEA has not confirmed one.
Sources
- ANTARA News, Oct. 8, 2026: KKSK agrees on SatuSehat Logistik oversight and a national kratom policy
- CNN Indonesia, Oct. 7, 2026: BPOM agenda at the KKSK meeting, from kratom to cell therapy
- Ministry of Higher Education, Science and Technology, Oct. 13, 2026: universities and industry on kratom research downstreaming
- IDX Channel, Oct. 17, 2026: Kimia Farma and BRIN explore eight health innovations including kratom
- HHS, Oct. 9, 2026: recommended science-based thresholds for 7-OH and MGPI
- Federal Register, Oct. 14, 2026: temporary placement of 7-OH and MGPI above a specified threshold (2026-20943)
- Pain News Network, Oct. 9, 2026: DEA’s 7-OH order amended, reported Nov. 13 effective date
- Ministry of Trade: kratom cannot yet be sold domestically but may be exported
- JDIH Kemendag: Ministerial Decision No. 1522 of 2026 on the kratom export rights percentage, July to December 2026
- ANTARA News, April 19, 2026: 200 to 300 tonnes of kratom exported monthly from Kutai Kartanegara
Not medical advice. This article is news reporting about law, regulation and research, and nothing in it is medical advice or a claim that kratom treats, cures or prevents any condition. Kratom can cause physical dependence and withdrawal with regular use. Legal status varies by state and by municipality and changes frequently. Talk to a qualified healthcare professional before using any kratom product, especially alongside other medicines.
